APLM

Apollomics Inc.

1.11 USD

Last updated Nov 30, 08:39 UTC

Yesterday HIGH

$1.16

Yesterday LOW

$1.09

52w HIGH

$49

52w LOW

$0.55

EPS

-2.55

PE

-0.44

Next Earnings

Dec 12, 2023

Overview News Government Trades

Apollomics Inc. stock is up 38.75% since 30 days ago. The next earnings date is Dec 12, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 2 November’s closed higher than October. 100% of analysts rate it a buy.

N/A

Stock Exchange

-

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Lisa Levin

Mon Oct 23, 2023

Crude Oil Falls Sharply; Apollomics Shares Plunge

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded down 0.19% to 33,062.85 while the NASDAQ rose 0.80% to 13,088.09. The S&P 500 also rose, gaining, 0.28% to 4,236.12.
Lisa Levin

Mon Oct 23, 2023

Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction.
Benzinga Insights

Mon Oct 23, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
Lisa Levin

Mon Oct 23, 2023

Nasdaq Turns Higher; Akumin Shares Jump

U.S. stocks pared losses midway through trading, with the Nasdaq Composite gaining over 60 points on Monday. The Dow traded down 0.01% to 33,126.50 while the NASDAQ rose 0.54% to 13,054.00. The S&P 500 also rose, gaining, 0.29% to 4,236.55.
Benzinga Insights

Mon Oct 23, 2023

12 Health Care Stocks Moving In Monday's Pre-Market Session
ryanfaloona@benzinga.com

Mon Oct 23, 2023

Market-Moving News for October 23rd

LMDX: 387% | LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England's First Heart & Lung Screening Hub APLM: 34% | Apollomics Announces Efficacy of Vebreltinib in
Benzinga Newsdesk

Mon Oct 23, 2023

Apollomics Announces Efficacy Of Vebreltinib In NSCLC Patients With MetEx14 Skipping Mutation Achieving An Overall Response Rate Of 75%

Apollomics Inc. (NASDAQ:APLM) (the "Company"), today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Medical Oncology Congress (ESMO) 2023,
Benzinga Insights

Fri Oct 20, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Newsdesk

Tue Oct 17, 2023

Apollomics To Presents Two Abstracts Detailing Vebreltinib Data At ESMO 2023
Benzinga Newsdesk

Tue Oct 3, 2023

HC Wainwright & Co. Maintains Buy on Apollomics, Lowers Price Target to $17

HC Wainwright & Co. analyst Robert Burns maintains Apollomics (NASDAQ:APLM) with a Buy and lowers the price target from $18 to $17.